NORVIR

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug NORVIR contains one active pharmaceutical ingredient (API):

1 Ritonavir UNII O3J8G9O825 - RITONAVIR

Ritonavir is an orally active peptidomimetic inhibitor of the HIV-1 and HIV-2 aspartyl proteases. Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor which leads to the production of HIV particles with immature morphology that are unable to initiate new rounds of infection. Ritonavir has selective affinity for the HIV protease and has little inhibitory activity against human aspartyl proteases. Pharmacokinetic enhancement by ritonavir is based on ritonavir’s activity as a potent inhibitor of CYP3A-mediated metabolism. Read about Ritonavir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NORVIR Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AE03	Ritonavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10273Q
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 543715070001617, 543718100003903
Country: CA	Health Products and Food Branch	Identifier(s): 02357593
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 2-MEE-1213
Country: EE	Ravimiamet	Identifier(s): 1109281, 1197873, 1285961, 1460113, 1460124, 1504482, 1580206, 1696686
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 196016009, 96016005
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 036290
Country: FR	Base de données publique des médicaments	Identifier(s): 65102533, 67851855
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 171734, 329059
Country: HK	Department of Health Drug Office	Identifier(s): 61528
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7219
Country: JP	医薬品医療機器総合機構	Identifier(s): 6250011F1024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1008592, 1008594, 1029813, 1053215, 1053216, 1058042, 1061352, 1080819
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 244M2012
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 129690, 45128, 94064
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 13812
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100223530, 100387881
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64691001
Country: SG	Health Sciences Authority	Identifier(s): 14288P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8680656080179, 8680656080308, 8699548191084
Country: US	FDA, National Drug Code	Identifier(s): 0074-1940, 0074-3333, 0074-3399, 53808-1119, 67296-1234
Country: ZA	Health Products Regulatory Authority	Identifier(s): 31/20.2.8/0216, 31/20.2.8/0217, 44/20.2.8/0128, 51/20.2.8/0154